Rights to ADXS-HPV Immunotherapeutic Vaccine

GBP has the rights to develop, manufacture, marketing and sales, and sublicense ADXS-HPV, immune therapeutic vaccine, in most part of Asia, the former Soviet Union and most African countries. The GBP territory covers 84 countries with over 3.8 billion in population.(Red Area)